SPECIALTY TOPICS

CURRENTLY VIEWING
Immunotherapy in Melanoma

Immunotherapy in Melanoma

Adjuvant Nivolumab Approved in Europe for Melanoma

The European Commission has approved nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, regardless of BRAF mutation status.
Read More >>

EU Panel Backs Adjuvant Nivolumab for Melanoma

FDA Accepts Application for Adjuvant Pembrolizumab for Stage III Melanoma

Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma

AACR 2018: Adjuvant Pembrolizumab Improves RFS in Stage III Melanoma

FDA Approves 4-Week Nivolumab Dosing Schedule

View More Stories >>

View Conference Coverage

2018 International Lung Cancer Congress

2018 Pan Pacific Lymphoma Conference

2nd Annual Live Medical Crossfire® : Hematologic Malignancies

State of the Science Summit on A Summer of Progress: Updates from ASCO 2018

2018 State of the Science Summit on Breast Cancer

Dr. Weber Discusses Updated Data for CheckMate-238

Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

Dr. Whitman on the Role of Pembrolizumab in Melanoma

Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma

Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Advances in Treating Melanoma: Closing Thoughts

COMBI-AD: Dual-Targeted Therapy for Stage 3 Melanoma

Alternative Approaches to Treating Melanoma

Emerging Agents and Combinations for Advanced Melanoma

Considering Chemotherapy's Value in Melanoma

Melanoma: Mechanisms of Resistance to Therapy

Targeting NRAS Mutations in Metastatic Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Less Common Side Effects With Immunotherapy in Melanoma

Immunotherapy in Melanoma: Recognizing an Endocrinopathy

Melanoma: Testing for Immunotherapy-Related Hepatotoxicity

Immunotherapy-Related Pulmonary Toxicities in Melanoma

Melanoma: Management of Dermatologic Toxicities

Overall Toxicities With Immunotherapy in Melanoma

Monotherapy Versus Combination Therapy Approaches in Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Metastatic Melanoma: The New Millennium

Keith Flaherty, MD, moderates this discussion with Rene Gonzalez, MD, Jason Luke, MD, FACP, and Jeffrey Weber, MD, PhD. The panel of experts in melanoma research and treatment talk about the most recent advances in the field, and provide perspective on how to apply the newest data to individualize treatment strategies.

View Now

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, and investigator at the Ludwig Center at Harvard, discusses the results of a 5-year follow-up analysis of survival outcomes of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

View Now